APR 19, 2017 8:02 PM PDT

Resilient T Cells Provide Cancer Treatment and Immunity

WRITTEN BY: Kara Marker

A key part of the process to create immunotherapies for the treatment of cancer involves rapid expansion protocols (REPs) and immune cells extracted from hosts. The idea is to put the immune cells back once they have been altered to be bigger and better at killing cancer, but previous targets, namely CD8+ T cells, lose their power after going through REPs. However, scientists have now identified a better target cell that could completely change immunotherapy approaches.

FierceBiotech

CD8+ T cells might not be cut out for long-term REPs, a necessary step in adoptive cancer immunotherapy (ACT). Th17 cells, though, appear to be uniquely eligible for the task; as compared to CD8+ T cells that show reduced efficacy after going through REPs, Th17 cells are more resilient and durable throughout the expansion process.

As an immunotherapy approach, ACT revolves around “The Three Es:” extracting, expanding, and enhancing host T cells for eventual return to the body to fight cancer. REPs are necessary but tough on T cells, and it can take up months to adequately prepare cells. After several weeks of preparation, CD8+ T cells often lose their power, but Th17 cells have been shown to be “resistant to expansion-induced degradation,” making them an obvious replacement for the seemingly “delicate” CD8+ cells.

"Th17 cells have a natural propensity to logarithmically expand without restimulation,” explained research leader Chrystal Paulos, PhD. “And, if we did restimulate them, this approach didn't dramatically impair the antitumor response as with CD8+ T cells."

What makes Th17 cells special? Stem cell-like properties. Paulos’s study showed that Th17 cells produced five thousand times the original number of cells when expanded for three weeks outside of the body thanks to their “natural propensity.”

Credit: Dr. Chrystal Paulos and Jacob Bower

In addition to retaining stem memory, resisting degradation, and effectively targeting melanoma in a mice model, after extraction and two weeks of expansion Th17 cells also remained in the tumor-bearing host after being returned to the body, indicating a protective effect for any possible recurrences of the cancer.

“When we rechallenged the same animals with another lethal tumor dose, these mice were protected but the control mice died quickly,” Paulos said. “Then we came back again 100 days later and gave these mice lung tumors and they were all still protected many months later."

Even more promising, the “remarkably potent antitumor response” seems to be extendable to the treatment of other cancer types, with an anti-cancer immunity effect “superior” to that obtained by classic applications of immunotherapy.

Sources: Medical University of South Carolina, JCI Insight

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 12, 2020
Drug Discovery & Development
FEB 12, 2020
Does Traditional Chinese Medicine Work Against Coronavirus?
Over 45,000 cases of Wuhan Coronavirus have been reported globally, alongside over 1,100 deaths. Although over 4,700 peo ...
APR 15, 2020
Immunology
APR 15, 2020
Why More Men than Women Die from COVID-19
As of April 9th, over 60% of deaths from COVID-19 in New York state were men. Meanwhile, as of April 6, 82% of patients ...
APR 15, 2020
Immunology
APR 15, 2020
How Malaria Protects Itself from the Immune System
A specific parasitic species causes the most deaths from malaria: Plasmodium falciparum. This parasite does so by avoidi ...
MAY 04, 2020
Immunology
MAY 04, 2020
GeoVax and Sino Bio Collaborate on COVID-19 Vaccine Work
GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ...
MAY 17, 2020
Coronavirus
MAY 17, 2020
Substantial Antiviral Response Seen in Adults Recovered from COVID-19
Some good news comes as researchers scramble for potential vaccine candidates amidst the global COVID-19 pandemic. Scien ...
MAY 26, 2020
Immunology
MAY 26, 2020
The Hunt for Rare Immune Cells, to InfinityFlow and Beyond
The immune landscape is staggeringly complex, with a myriad of genetically and functionally distinct immune cell subpopu ...
Loading Comments...